A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically verified colorectal adenocarcinomas * Age \> 18 years * Metastatic colorectal cancer refractory to 5-FU, oxaliplatin, irinotecan and relevant biological agents. * Measurable disease according to RECIST 1.1 * ECOG performance status 0, 1 or 2 * Adequate renal, hepatic and haematological function * Consent to blood samples and available paraffin embedded tumour material for translational research studies * Fertile males and females (\<2 years after last period for women) must use effective birth control. * Signed Informed consent Exclusion Criteria: * Clinically significant concurrent disease. * Other malignant diseases within 5 years of inclusion in the study, except squamous cell carcinoma of the skin and cervical carcinoma-in-situ. * Other experimental therapy within 30 days of treatment initiation. * Patients who are breast feeding, childbearing or of childbearing potential without using dual effective contraception. * Clinical or radiological evidence of CNS metastasis. * Planned radiation therapy against target-lesions. * Known allergy to 5FU/capecitabine or gemcitabine.